Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen's Leqembi for patients with Alzheimer's disease, clearing the way for wider insurance coverage of the drug.

US FDA grants standard approval of Eisai/Biogen Alzheimer's drug

The U.S. Food and Drug Administration on Thursday granted full approval to the Biogen BIIB and Eisai Co. Ltd. ESALF Alzheimer's treatment Leqembi, a step that secures Medicare reimbursement for the first drug shown to slow the progress of the disease, rather than just treating its symptoms.

FDA approves Biogen and Eisai Alzheimer's treatment Leqembi

The FDA could fully approve Biogen's Alzheimer's treatment, Leqembi, on Thursday. The decision could give a lift to Biogen stock.

Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment

Agilent Technologies

Autodesk

Amgen

Bank of America

Bank of New York Mellon

Blackrock Inc

Comcast

CME Group

Compass Minerals

Campbell Soup

Copart

Cheniere Energy Partners

Corteva Inc

Disney

Domino's Pizza

Ecolab

Equifax

Estee Lauder

Emerson Electric

Etsy

General Dynamics

Gilead Sciences

Alphabet

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map

CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community. The data were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA this week in Orlando, Fla.

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

The FDA could soon make a decision on Biogen's Alzheimer's drug, Leqembi. An advisory committee confirmed its clinical benefits, suggesting an approval could be ahead.

Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?

Some European Alzheimer's experts are wary about the future of Biogen's drug Leqembi in the region. Regulators in Europe, the U.S., and Japan currently are reviewing the drug.

Does This Signal Trouble for Biogen's New Alzheimer's Drug?

Vertex Pharmaceuticals

Vertex's next blockbuster could generate billions of dollars in sales. Biogen is inching closer to a goal it's been working on for a long time.

2 Market-Beating Stocks With Major Catalysts on the Way

Archer-Daniels-Midland Company

CF Industries Holdings

Marathon Petroleum

Snap-on

Valero Energy

When attempting to build a portfolio of reliable entities, you probably can't go wrong with undervalued S&P 500 stocks. Featuring the market performance of 500 of the largest companies listed on stock exchanges in the U.S., you're dealing with proven winners.

7 Undervalued S&P 500 Stocks to Buy in June

After a 13% rise in Biogen stock (NASDAQ: BIIB) this year, aligning with the broader S&P500 index returns, we believe it has little room for growth.

What's Happening With Biogen Stock?

Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.

European Alzheimer's experts unconvinced by new Eisai, Biogen drug

CAMBRIDGE, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced several changes to its Board of Directors today. The changes will refresh the composition of the Board and follow the Board's continual interaction with company stockholders to solicit their perspective on a range of issues around the company's performance and strategy.

Biogen Announces Changes to Its Board of Directors

Biogen (NASDAQ: BIIB ) stock is a hot topic among traders on Monday as the company's share resumed trading following a halt that was in effect on Friday. With that halt coming to an end, investors in BIIB stock are also celebrating a new recommendation from the FDA.

BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing

An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.

Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement

Biogen Inc (NASDAQ:BIIB) shares rose in pre-market trading on Monday after a Food and Drug Administration (FDA) panel voted in favor of Eisai and Biogen's drug LEQEMBI as a treatment for Alzheimer's disease, clearing the way for traditional approval of the drug. The FDA Peripheral and Central Nervous System Drugs Advisory Committee said on Friday that data from a global Phase 3 trial in Alzheimer's patients confirmed the clinical benefit of LEQEMBI in the disease, according to a statement from Biogen.

Biogen shares rise on imminent approval of Alzheimer's drug following FDA panel vote

Shares of Biogen Inc rose 4% in premarket trade on Monday as an unanimous backing of the company's Alzheimer's drug Leqembi by the U.S. regulator's advisers eased concerns that a traditional approval for the treatment will not come with major new safety warnings.

Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns

Oracle

Biogen Inc. shares BIIB, +1.31% rallied 5% following a full-day halt during the regular session as a Food and Drug Administration committee convened to vote on an approval recommendation for the biotech's Alzheimer's drug candidate it makes with Eisai Co. ESALF, +9.35% The committee voted unanimously to recommend approval, and Biogen shares took off when they were unhalted.

Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move

Shares of Biogen Inc (NASDAQ: BIIB) gained nearly 10% in extended hours after the biotech firm edged closer to winning FDA approval for its Alzheimer's drug. FDA panel greenlights Biogen's Leqembi Late on Friday, advisory committee of the U.S. Food and Drug Administration unanimously recommended Leqembi for the treatment of Alzheimer's disease.

Biogen inches closer to FDA approval for its Alzheimer's drug

Biogen Inc. BIIB, +1.31% shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and Drug Administration advisory committee to approve an Alzheimer's treatment it makes with Eisai Co. ESALF, +9.35% Biogen shares rallied as much as 9% after hours, after spending the regular session halted at $308.88.

Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer's drug for approval

Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer's disease

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Biogen stock was halted Friday as a panel of experts to the FDA debated the merits of its Alzheimer's treatment, Leqembi.

Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment

Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment.

FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval

A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.

FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen

Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.

Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod

Mobileye Global Inc

Vector Group

A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils 3 juicy setups.

News for Biogen Stock (BIIB)